Oyster Point Pharma, Inc. OYST
We take great care to ensure that the data presented and summarized in this overview for Oyster Point Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OYST
View allLatest Institutional Activity in OYST
Top Purchases
Top Sells
About OYST
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Insider Transactions at OYST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2023
|
Inv Opps Gp Iv, L.L.C. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,768,586
-100.0%
|
-
|
|
Jan 03
2023
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,420,730
-100.0%
|
-
|
|
Jan 03
2023
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,236,888
-100.0%
|
-
|
|
Jan 03
2023
|
Aimee S Weisner Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,764
-95.14%
|
-
|
|
Jan 03
2023
|
New Enterprise Associates 14, L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,925,287
-100.0%
|
-
|
|
Jan 03
2023
|
Ali Behbahani Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,639
-86.9%
|
-
|
|
Jan 03
2023
|
Michael G Atieh Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,671
-100.0%
|
-
|
|
Jan 03
2023
|
Michael G Atieh Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
18,063
-67.57%
|
-
|
|
Jan 03
2023
|
George Christopher Eliades Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,624
-70.54%
|
-
|
|
Jan 03
2023
|
Daniel Lochner Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,236
-100.0%
|
-
|
|
Jan 03
2023
|
Daniel Lochner Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,289
-73.56%
|
-
|
|
Jan 03
2023
|
Mark Anthony Murray Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
122,086
-98.54%
|
-
|
|
Jan 03
2023
|
Jeffrey Nau President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,000
-100.0%
|
-
|
|
Jan 03
2023
|
Jeffrey Nau President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
47,975
-100.0%
|
-
|
|
Jan 03
2023
|
Jeffrey Nau President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
100,738
-67.74%
|
-
|
|
Jan 03
2023
|
Clare Ozawa Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,657,618
-100.0%
|
-
|
|
Jan 03
2023
|
Clare Ozawa Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,637
-87.79%
|
-
|
|
Jan 03
2023
|
Donald J Santel Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,198
-100.0%
|
-
|
|
Jan 03
2023
|
Donald J Santel Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,489
-40.1%
|
-
|
|
Jan 03
2023
|
Benjamin Tsai Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,573
-100.0%
|
-
|